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Abstract
Preclinical studies in animals and ex vivo human blood have
provided a solid rationale for conducting prospective randomized
trials in trauma patients. Small animal models have been utilized to
study the efficacy of recombinant activated factor VII (rFVIIa;
NovoSeven®) in treating thrombocytopenic rabbits and for the
reversal of anticoagulation. Safety models in the rabbit also exist to
test for systemic activation of clotting and pathologic thrombosis.
Animal models simulating traumatic injuries in humans have
primarily been performed in pigs because of species similarities in
terms of coagulation characteristics and the larger internal organs.
The pig studies, utilizing human rFVIIa, have shown increased
strength of clot formation, decreased bleeding, and improved
survival. However, these findings are not uniform and are
dependant on the model chosen. All of the animal models
described have provided good safety data and suggest that the
use of rFVIIa is not associated with systemic activation of
coagulation or microthrombosis of end organs.
Introduction
Animal models utilizing human recombinant activated factor
VII (rFVIIa; NovoSeven®; Novo Nordisk A/S, Bagsværd,
Denmark) are limited by interspecies differences in terms of
coagulation molecule interactions. The interaction between
tissue factor and factor VIIa is species specific [1,2]. Human
factor VII has been shown to have reduced activity when it is
exposed to porcine thromboplastin. These considerations are
compounded by the fact that the majority of standard in vitro
coagulation assays are performed with rabbit brain
thromboplastin. Both rabbit and human thromboplastin
induce coagulation more efficiently in human plasma than in
swine plasma [3]. Therefore, changes in coagulation
parameters seen with the use of human rFVIIa in animals may
not correlate with hemostatic end-points.
Because of these interspecies differences with regard to
human rFVIIa activity, minimal conclusions concerning optimal
dosing in humans can be drawn from animal experiments. In
pharmacologic models the dose of rFVIIa needed for effect
varies substantially between animal species, including the
dog (60 µg/kg) [4], rabbit (2 mg/kg) [5], and mouse
(10 mg/kg) [6].
Small animal models
Rabbits and rats are the basis of the small animal models.
Tranholm and coworkers [5] produced thrombocytopenia in
rabbits with γ radiation and platelet antibodies. Animals given
2 mg/kg rFVIIa had decreased time of bleeding and blood
loss compared with control animals. There was no evidence
of microthrombosis in the kidneys of these animals. The
efficacy of reversing a bolus of low-molecular-weight heparin
(LMWH) was studied in a rabbit ear puncture model [7].
Animals were given 1800 anti-factor X units/kg of LMWH,
which raised the primary bleeding time approximately fourfold.
rFVIIa did not reduce bleeding time or blood loss in this
model. The absence of efficacy was hypothesized to be
secondary to very high anti-factor Xa levels produced by
bolus dosing of LMWH.
The efficacy of rFVIIa in reversing the effects of coumadin and
the direct thrombin inhibitor melagatran has also been
studied in a rat tail bleeding model. The use of rFVIIa resulted
in decreased blood loss in animals given warfarin once but it
did not reduce blood loss significantly in animals given
warfarin twice [8]. In rats given melagatran, 1 mg rFVIIa
resulted in a decreased bleeding time but no significant
reduction in blood loss [9].
Studies assessing safety have also been performed in small
animal models. The effect of rFVIIa administration on
dissemination of clotting and thrombogenicity was investi-
gated in the rabbit. In a model of stasis-induced thrombosis,
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administration of rFVIIa at a dose that enhanced clot
formation at the site of injury resulted in no change in platelet
count or the plasma concentration of antithrombin, indicating
that rFVIIa was not associated with systemic activation of
coagulation [10]. In an experimental model of arterial
thrombosis, rFVIIa given in concentrations that decreased ear
bleeding time and blood loss from incision sites in the liver
and spleen did not affect arterial thrombosis [11].
Pig studies
Currently, three swine trauma models exist in the literature for
the study of the efficacy and safety of rFVIIa. These models
include a grade V liver injury model, a liver avulsion model,
and an infrarenal aortotomy model. In addition to differences
in the mechanism and site of injury, these models also differ
with respect to animal temperature and coagulation status,
timing and rate of resuscitation, timing and dose of therapy,
and use of conventional therapies.
The first of these studies, reported by Martinowitz and
coworkers [12], utilized a specially designed clamp to create
a grade V liver injury based on American Association for the
Surgery of Trauma organ injury scaling criteria (Fig. 1) [13].
Prior to injury, 10 animals underwent a 60% isovolemic
exchange transfusion with 6% hydroxyethyl starch and
cooling to 33°C. Thirty seconds after injury, blinded therapy,
consisting of either 180 µg/kg rFVIIa or saline, was given and
liver injuries were packed with gauze. Resuscitation with
40°C lactated Ringer’s was initiated at 250 ml/min 5.5 min
after injuries. Animals were resuscitated and maintained at
their baseline blood pressure for the 1-hour study period.
Treatment with rFVIIa resulted in a statistically significant
reduction in blood loss from 976 cc to 527 cc. Treatment
also resulted in significant reduction in prothrombin time, and
elevation in the FVII clotting activity (FVII:C) was observed.
Postmortem analysis revealed no evidence of large clots in
the hepatic veins or inferior vena cava and no evidence of
microthrombosis.
In a follow-up study, Schreiber and coworkers [14] repeated
the analysis with minor differences in the model used. The
60% isovolemic hemodilution was performed with 5%
albumin instead of hydroxylethyl starch to avoid the potential
coagulopathic effects of starch solutions. The creation of the
dilutional coagulopathy resulted in a hypotensive state with a
starting mean arterial pressure of 45 mmHg. Blinded therapy,
packing, and initiation of resuscitation were performed
simultaneously at 30 s and animals were resuscitated with
lactated Ringer’s at 100 ml/min. The temperature of the
resuscitation fluid was varied to maintain animal temperature
at 33°C. Three groups of 10 animals were given either
180 µg/kg rFVIIa, 720 µg/kg rFVIIa, or an equivalent amount
of buffer solution. Similar to the study conducted by
Martinowitz and coworkers, animals treated with rFVIIa had
significantly less blood loss than did controls (control animals
2187 ml, 180 µg/kg group 1085 ml, and 720 µg/kg group
1086 ml). Nadir blood pressures following injury were
significantly lower in control animals than in treated animals.
Treated groups also had significantly lower prothrombin times
and higher thrombin–antithrombin complexes, suggesting
activation of thrombin. Death occurred in four out of 10
controls, three out of 10 in the 180 µg/kg group, and two out
of 10 in the 720 µg/kg group. These differences did not
achieve statistical significance. The only difference between
the animals that received 720 µg/kg rFVIIa and 180 µg/kg
rFVIIa was a dose-dependent increase in FVII:C levels
following delivery of drug.
The same investigators also tested the efficacy of rFVIIa as
sole therapy in noncoagulopathic, normothermic animals [15].
In this study, 30 animals were randomly assigned to receive
either 150 µg/kg rFVIIa or an equivalent volume of buffer
solution 30 s after injury. Animals were resuscitated with
warmed lactated Ringer’s solution at 100 ml/min initiated
15 min after injury to maintain their baseline blood pressure
and normothermia (38°C) for the 2-hour study period. Liver
injuries were not treated in this model. Despite documen-
tation of a significant increase in FVII:C and decrease in
prothrombin time, there was no difference in blood loss
between groups. Blood pressure curves were similar and
thrombin–antithrombin complexes became equally elevated
between groups throughout the study. Potential explanations
for the failure of rFVIIa to reduce blood loss in this model
included the use of the drug as a sole agent in this large
venous injury model and the normotensive state of the
animals at the start of the study compared with the hypo-
tensive state produced in the dilutional coagulopathy model.
Lynn and coworkers [16] described a reproducible grade IV
liver injury whereby a clamp was utilized to crush and avulse
the left median liver lobe and major vessels of the left lateral
lobe. In the first study using this model, 13 animals were
randomly assigned to receive 180 µg/kg rFVIIa or blinded
placebo given when the mean arterial blood pressure
dropped by 10% of baseline. The study was continued for
1 hour without resuscitation. Animals receiving rFVIIa had
Figure 1
Clamp designed to create a grade V liver injury based on organ injury
scaling criteria from the American Association for the Surgery of
Trauma [12,13].S27
significantly higher blood pressures after treatment than did
control animals. Blood loss in the treatment group was
33 ml/kg versus 27 ml/kg in the control group (P = 0.2).
Mortality was 43% in the control group and 0% in the
treatment group (P = 0.08). All deaths occurred during the
first 15 min of the study. Animals receiving rFVIIa had a
significantly lower prothrombin time after treatment than did
controls.
These investigators used the same model to study 24 animals
divided into three groups [17]: control (group 1); 180 µg/kg
rFVIIa (group 2); and 720 µg/kg rFVIIa (group 3). The study
drug was again given following a 10% drop in mean arterial
pressure following grade IV liver injury. This follow-up study
was continued for 2 hours after treatment. Death occurred in
four out of eight in group 1, two out of eight in group 2, and
none of eight in group 3 during the first hour (P = 0.02 for
control versus 720 µg/kg). All deaths in the first two groups
occurred within 22 min and the only death in the third group
occurred at 116 min. Blood loss was significantly less in
group 3 than in group 1. Prothrombin times were significantly
less in the treated groups than in the control group. Blood
loss and prothrombin times were not statistically different
between rFVIIa treated groups. There was no evidence of
microthrombosis or macrothrombosis within viewed sections
of kidney, mesentery of small intestine, small intestine wall,
lung, heart, or brain in the treated groups.
The final animal study described in this review was designed
by Sondeen and coworkers [18] to test the efficacy of rFVIIa
in producing stronger clots and elevating the blood pressure
at which rebleeding occurs in a pig aortotomy model. By
elevating the blood pressure at which rebleeding occurs,
rFVIIa would theoretically permit more effective resuscitation
without increasing blood loss. Thirty pigs were randomly
assigned to a control group, a 180 µg/kg group, or a
720 µg/kg group. Blinded treatment was administered 5 min
before injury. A skin biopsy punch was used to make a 2 mm
hole in the infrarenal aorta. Resuscitation was initiated 10 min
after injury with lactated Ringer’s at 100 ml/min. If rebleeding
did not occur before the mean arterial pressure achieved a
plateau after administration of 4 l resuscitation fluid, animals
were given epinephrine (adrenaline) to raise the blood
pressure to a maximum of 200 mmHg. Animals that failed to
rebleed with this treatment were classified as non-rebleeders.
Resuscitation was given to maintain the baseline blood
pressure for the 2-hour study period.
The rebleeding blood pressure in the control group was
significantly lower (45 mmHg) than that in the 180 µg/kg
group (69 mmHg) and the 720 µg/kg group (66 mmHg) [18].
There was a trend toward greater rebleed volume in the
control group (39 ml/kg in controls versus 22 ml/kg and
26 ml/kg for the 180 µg/kg and 720 µg/kg groups,
respectively). Four of 10 animals required epinephrine in the
high-dose group versus one out of 10 in each of the other
two groups. Significantly more animals in the control group
(nine out of 10 animals) rebled at mean arterial pressures
below baseline than in the rFVIIa groups (two out of 10
animals). rFVIIa-treated animals received significantly more
fluid resuscitation before rebleeding than did control animals.
Similar to prior studies, FVII:C exhibited a dose-related
increase in the two treatment groups. Prothrombin times
were equally lowered in the two treatment groups.
Ex vivo human blood studies
Cohort studies in humans have suggested that there is a
population of patients who do not respond to treatment with
rFVIIa [19,20]. This group of patients includes those
extremely ill individuals with the lethal triad of hypothermia,
coagulopathy, and acidosis who are on pressor therapy. It
also includes those with irreversible hemorrhagic shock, who
are unlikely to respond to any therapy. Based on these
findings, Meng and coworkers [21] attempted to determine
the effects of temperature and acidosis on factor VIIa activity
utilizing blood from healthy adults. Factor VIIa activity on
phospholipid vesicles and on platelets was measured by
determining factor Xa generation in the presence and
absence of tissue factor. Tissue factor dependent factor Xa
generation increased with an increase in temperature from
24°C to 37°C, whereas tissue factor-independent factor Xa
generation decreased to an equal degree. This resulted in no
overall change in factor VIIa activity with changes in
temperature. Alternatively, reduction in pH resulted in marked
diminution in factor VIIa activity from both tissue factor
dependent and independent mechanisms. The authors
concluded that acidosis effects overall factor VIIa activity but
that hypothermia does not.
Conclusion
The efficacy and safety of rFVIIa has been demonstrated in
multiple small and large animal models. Because of species
specific differences in the interaction between human rFVIIa
and animal tissue factor, comments regarding dosing remain
guarded. However, there does appear to be a maximum dose
above which no additional benefit is achieved. Published ex
vivo data suggest that rFVIIa may not be effective in severely
acidotic environments. Preclinical data strongly support
progression to prospective randomized trials in humans.
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